Ralaniten
Ralaniten
Ralaniten (pronounced rah-LAN-ih-ten) is a non-steroidal antiandrogen (NSAA) that is used in the treatment of prostate cancer. It is also known by its developmental code name EPI-506.
Etymology
The name "Ralaniten" is derived from the chemical structure of the compound, which includes a raloxifene moiety and an anilide moiety. The "-iten" suffix is common in the names of drugs that act as inhibitors.
Pharmacology
Ralaniten works by binding to the androgen receptor and blocking its interaction with androgens, which are hormones that promote the growth of prostate cancer cells. It is a unique type of NSAA because it targets the N-terminal domain of the androgen receptor, which is not targeted by other NSAAs.
Clinical use
Ralaniten is used in the treatment of prostate cancer, particularly in cases that are resistant to other treatments. It is usually administered orally.
Related terms
External links
- Medical encyclopedia article on Ralaniten
- Wikipedia's article - Ralaniten
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski